Becton, Dickinson and Company (NYSE:BDX) Updates FY 2025 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 14.300-14.600 for the period, compared to the consensus earnings per share estimate of 14.350. The company issued revenue guidance of $21.7 billion-$21.9 billion, compared to the consensus revenue estimate of $21.9 billion.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent research reports. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded up $1.09 during midday trading on Friday, hitting $228.30. The stock had a trading volume of 1,343,209 shares, compared to its average volume of 2,164,556. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a market capitalization of $66.21 billion, a PE ratio of 38.45, a P/E/G ratio of 1.80 and a beta of 0.40. The stock has a 50 day simple moving average of $231.90 and a 200-day simple moving average of $234.05. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Becton, Dickinson and Company announced that its board has approved a share buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Activity

In other news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the transaction, the executive vice president now directly owns 6,141 shares in the company, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock valued at $2,210,716 in the last quarter. Insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.